Table 2.
Quantitative changes in QoL induced by the switch to PAS-LAR monotherapy and in combination with PEGV combined
| Baseline median (IQR) n = 51 |
PAS-LAR (9 months) median (IQR) n = 51 |
P values | |
|---|---|---|---|
| PASQ total | 14.0 (7.0–21.3) | 10.0 (6.0–19.0) | 0.090 |
| PASQ headache | 1.0 (0.0–3.0) | 1.0 (0.0–2.0) | 0.014 |
| PASQ excessive perspiration | 2.0 (0.0–3.8) | 2.0 (0.0–4.0) | ns |
| PASQ osteoarthralgia | 3.5 (1.0–5.0) | 3.0 (1.5–4.5) | ns |
| PASQ fatigue | 3.0 (2.0–5.0) | 3.0 (1.5–5.0) | 0.0074 |
| PASQ soft tissue swelling | 2.0 (0.0–3.0) | 1.0 (0.0–3.0) | ns |
| PASQ paresthesia | 1.0 (0.0–3.0) | 1.0 (0.0–3.0) | ns |
| PASQ overall health status | 3.0 (2.0–6.0) | 3.0 (2.0–5.0) | ns |
| AcroQoL global (%) | 66.4 (60.0–77.3) | 71.8 (65.0–82.7) | ≤0.0001 |
| AcroQoL physical (%) | 31.4 (25.7–35.7) | 35.7 (29.3–40.0) | ≤0.0001 |
| AcroQoL psychological (%) | 70.7 (64.3–78.6) | 72.9 (65.0–85.7) | 0.0051 |
| AcroQoL personal relations (%) | 80.0 (68.6–88.6) | 82.9 (71.4–88.6) | ns |
| AcroQoL appearance (%) | 62.9 (54.3–77.1) | 65.7 (54.3–77.1) | 0.0095 |
AcroQoL Acromegaly Quality of Life, IQR interquartile range, ns not significant, PAS-LAR pasireotide long-acting release, PASQ Patient-Assessed Acromegaly Symptom Questionnaire, PEGV pegvisomant